Insider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) CFO Purchases $10,036.75 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly bought 2,113 shares of the business’s stock in a transaction on Friday, December 27th. The shares were bought at an average cost of $4.75 per share, for a total transaction of $10,036.75. Following the completion of the acquisition, the chief financial officer now directly owns 40,186 shares in the company, valued at approximately $190,883.50. This trade represents a 5.55 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Precision BioSciences Price Performance

Shares of DTIL opened at $4.69 on Friday. The business has a 50-day moving average of $6.52 and a 200-day moving average of $8.48. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The company has a market capitalization of $35.98 million, a price-to-earnings ratio of 78.18 and a beta of 1.41. Precision BioSciences, Inc. has a 1 year low of $3.61 and a 1 year high of $19.43.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC lifted its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 65,974 shares of the company’s stock after buying an additional 19,088 shares during the quarter. Geode Capital Management LLC owned about 0.86% of Precision BioSciences worth $591,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.